Indian scientists and international collaborators have tested a five-part recombinant antivenom that protected mice from dangerous cobra and king cobra venoms found across India. Published in Science Translational Medicine on 9 September 2026, the study indexed by PubMed involved the Indian Institute of Science (IISc), the Technical University of Denmark and other partners. Instead of the broad antibody mixture collected from immunised horses, the experimental treatment uses five engineered antibody fragments called nanobodies. The work remains preclinical, but it raises a major question: could toxin-targeted antibody combinations eventually produce broader, more consistent snakebite treatment?
Key Highlights
- The experimental antivenom contains five recombinant nanobodies rather than horse-derived antibody mixtures.
- It targets alpha-neurotoxins, cytotoxins and phospholipases A2 found in cobra and king cobra venoms.
- Mouse tests showed protection against spectacled cobra, monocled cobra and two Indian king cobra species.
- Human safety, dosing and effectiveness still need to be established through further research and clinical trials.
What Did The Researchers Actually Build?
The team led by IISc’s Kartik Sunagar and collaborators including Andreas H. Laustsen and Anne Ljungars at DTU developed an oligoclonal recombinant antivenom. “Oligoclonal” means the treatment combines a small, selected group of antibodies instead of the much wider mixture found in conventional plasma-derived antivenom.
The five nanobodies were selected to recognise three toxin groups: alpha-neurotoxins, cytotoxins and phospholipases A2. These toxins can disrupt nerve signalling, damage cells and drive severe illness after envenoming.
The antibody fragments build on earlier camelid research involving animals such as alpacas and llamas. Scientists can produce these compact nanobodies through recombinant systems, allowing tightly defined components without repeatedly immunising horses.
IISc also shared the finding through its official X account on 10 September 2026, highlighting protection against geographically diverse Indian cobra and king cobra venoms.
How Strong Were The Results In Mice?
Researchers tested the cocktail against venom from the spectacled cobra, monocled cobra and two king cobra species, Ophiophagus kaalinga from the Western Ghats and Ophiophagus hannah from Northeast India. The paper reports protection in preincubation and rescue-style mouse models.
According to the official IISc research release, the cocktail prevented death even when researchers administered it after venom injection. In rescue experiments, treatment given as late as 30 minutes after exposure could still save mice. Sunagar also reported that animals showing paralysis or other neurotoxic signs returned to an asymptomatic state after treatment.
That finding is especially relevant because treatment begins after a bite. Even so, success in mice cannot establish the dose, timing or safety required for people.
Why Could This Point Towards A Broader Antivenom?
Snake venom differs between species and can vary geographically. India’s commonly used polyvalent antivenoms mainly target the “Big Four”: Indian cobra, common krait, Russell’s viper and saw-scaled viper. WHO India’s snakebite information says these snakes account for around 90% of bites, while other medically important species can still create treatment gaps.
The new strategy takes a toxin-first route. Researchers select antibodies that recognise toxin families shared across related snakes. In principle, scientists could add further antibody components when coverage is needed for other medically important venoms.
The field is already moving this way. A 2025 Nature study on recombinant nanobodies described an antivenom against several African elapid venoms. In February 2026, WHO also published its first target product profiles for novel snakebite treatments, including engineered antibodies and small-molecule treatments.
WHO estimates that 4.5 million to 5.4 million people are bitten by snakes each year, with 81,000 to 138,000 deaths. That burden keeps demand high for treatments that can cover more venom types with predictable manufacturing.
What Has To Happen Before People Can Receive It?
The mouse results are proof of concept, not a ready replacement for current antivenom. Researchers still need toxicology studies, manufacturing validation, dosing work and controlled human trials. They must show that the cocktail performs against clinically relevant venom doses and across different patient conditions.
A broader Indian antivenom would also need protection beyond cobras. Kraits and vipers carry different toxin profiles, so extra antibodies or other therapeutic components may be required. The five-nanobody cocktail shows that a modular approach can work in animals. The harder task is proving safety, affordability and practical use in patients.
FAQs
Q1. What is the new Indian antivenom made from?
It combines five recombinant nanobodies selected to block major toxin families found in cobra venoms.
Q2. Which snake venoms did researchers test?
Researchers tested spectacled cobra, monocled cobra and two Indian king cobra species from different regions.
Q3. Has the treatment been tested in humans?
No, researchers tested it in mice, and human clinical trials would still be required first.
Q4. Why are nanobodies useful for antivenom research?
Nanobodies are compact antibody fragments that can target toxins precisely and support recombinant antivenom production.
Q5. Could one future antivenom treat every snakebite?
Not yet; broader coverage needs added components targeting toxins from kraits, vipers and other snakes.
Stay Updated on Health, Jobs & Defence
What Does Karnataka’s HIV Report Reveal?
Check out the latest findings on HIV treatment coverage in Karnataka.
How Is AYUSH Coverage Changing Claims?
Find out how cashless AYUSH treatment could affect insurance claims.
Which Hospitals Accept Ayushman Cards?
Uncover how to check eligible private hospitals near you.
Who Can Apply for AP Jobs?
Browse the new Andhra Pradesh government job age-limit rules.
What Are Yudh Abhyas Troops Practising?
Explore what Indian and American troops are training for in 2026.
